FIELD: biotechnology.
SUBSTANCE: described is a modified enveloped virus selected from the group consisting of: herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), vaccinia virus, vesicular stomatitis virus (Indiana fever) (VSV), measles virus (MeV), Maraba virus and Newcastle disease virus (NDV), wherein said virus has at least one anti-tumour, tumour-specific peptide, non-genetically attached to the viral envelope or injected into/through the viral envelope. Also proposed is a pharmaceutical composition for treating cancer, containing: a modified enveloped virus according to any of the claims 1 to 17 and a corresponding carrier. Also described are methods for treating cancer.
EFFECT: invention expands the range of means of treating cancer.
24 cl, 13 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VIRUS VECTOR | 2020 |
|
RU2799418C1 |
| HERPES SIMPLEX SYNCYTIAL ONCOLYTIC MUTANTS AS POWERFUL THERAPEUTIC AGENTS FOR TREATING CANCER | 2020 |
|
RU2821999C2 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804772C2 |
| THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO IT | 2018 |
|
RU2797266C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804126C2 |
